Eli Lilly's Zepbound and Mounjaro weight-loss/diabetes drugs have limited supplies through mid-year due to surging demand, per the FDA.
Most doses of Eli Lilly's weight-loss drug Zepbound and diabetes treatment Mounjaro are in short supply through at least the middle of this year, due to surging demand, according to the U.S. Food and Drug Administration (FDA). Only the lowest dose of Zepbound, typically used short-term, is listed as available. The FDA previously stated that only two doses of Zepbound would be in limited supply through the end of April.
April 17, 2024
11 Articles